NCT02729766View on ClinicalTrials.gov

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Inappropriate ADH Syndrome
Interventions
OTHER

Induced hypotonic hyponatremia - SIAD model

DRUG

Empagliflozin 25mg Tbl

DRUG

Placebo P-Tablet

Trial Locations (1)

4031

Department Endocrinology University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT02729766 - Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Biotech Hunter | Biotech Hunter